Jump to content

Drilldown: Medicines

Pharmacopedia
BrowseCategoriesLog in
Pharmacopedia is being built in public. Pages may be incomplete.About this site

Choose a table:


Medicines > classes : Benzodiazepine or Classic Psychedelic or [[:Category:IBD_medications|IBD medication]]

Use the filters below to narrow your results.

generic:
brand:
None (78) · Asacol HD, Pentasa, Lialda, Apriso, Delzicol, Rowasa (rectal), Canasa (suppository) (1) · Dalmane (1) · Delysid (historical, Sandoz, withdrawn 1965) (1) · Doral (1) · Halcion (1) · Lexotan (1) · Librium (1) · Mogadon (1) · Onfi (1) · ProSom (1) · Restoril (1) · Rohypnol (1) · Serax (1) · Tranxene (1) · Versed (1) · Xanax (1)
classes: (Click arrow to add another value)
mechanism:
5-HT2A agonist (26) · GABAA positive allosteric modulator (18) · Potent 5-HT2A agonist (5) · LSD analogue; 5-HT2A agonist (4) · Prodrug of LSD; 5-HT2A agonist (4) · Contains LSA (2) · Contains mescaline (2)
uses:
None (92) · '"`UNIQ--vote-00000069-QINU`"', '"`UNIQ--vote-0000006A-QINU`"', '"`UNIQ--vote-0000006B-QINU`"' (1) · '"`UNIQ--vote-00000BBC-QINU`"', '"`UNIQ--vote-00000BBD-QINU`"' (1)
starting dose:
None (92) · 0.25 mg (1) · Active UC: Lialda 2.4-4.8 g PO once daily, Apriso 1.5 g PO once daily; maintenance 1.2-2.4 g/d; rectal Rowasa enema 4 g HS for distal disease; Canasa 1 g suppository HS for proctitis (1)
preparations:
None (92) · 0.25 mg, 0.5 mg, 1 mg, 2 mg tablets (immediate-release and orally disintegrating); 0.5 mg, 1 mg, 2 mg, 3 mg extended-release tablets; 1 mg/mL oral concentrate (1) · Multiple non-bioequivalent oral formulations (pH-, time-, and moisture-dependent release); rectal enema 4 g/60 mL; 1 g rectal suppository (1)
fda max:
None (92) · 10 mg/d (1) · Formulation-specific; ~4.8 g/d typical maximum oral (1)
routes:
None (91) · Oral (3) · rectal (1)
onset:
None (91) · 30-60 min (immediate-release); 1-2 h (extended-release) (1) · 30–60 minutes (1) · Symptomatic improvement 2-4 weeks (1)
duration:
None (91) · 24 hours (most ER formulations) (1) · 6 h (immediate-release); ~11 h (extended-release) (1) · 8–12 hours (1)
halflife:
None (91) · 11-13 h (immediate-release); 11-16 h (extended-release) (1) · 3–5 hours (1) · ~5-10 hours (5-ASA)'"`UNIQ--ref-00000BBE-QINU`"' (1)
bioavailability:
None (91) · 70–90% (oral) (1) · 80-90% oral (1) · Highly formulation-dependent; the goal is colonic delivery with minimal systemic exposure'"`UNIQ--ref-00000BBF-QINU`"' (1)
pregnancy:
None (91) · Category D'"`UNIQ--ref-0000006C-QINU`"' (1) · Generally considered safe at standard doses; benefits typically outweigh in active IBD.<sup class="pcp-cn" title="This claim needs a citation.">&#91;[[Pharmacopedia:Citation needed|citation&nbsp;needed]]&#93;</sup> (1) · Not established (1)
legal:
None (91) · Schedule I (United States) (1) · Schedule IV (US) (1) · [[USLegal:Prescription only|Rx-only]] in US (1)

Showing below up to 94 results in range #1 to #94.

View (previous 250 | next 250) (20 | 50 | 100 | 250 | 500)


View (previous 250 | next 250) (20 | 50 | 100 | 250 | 500)

Retrieved from "https://pharmacopedia.wiki/p/Special:Drilldown/Medicines"